Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial

被引：0

作者：

Nobuya Inagaki

Wenying Yang

Hirotaka Watada

Linong Ji

Sven Schnaidt

Egon Pfarr

Tomoo Okamura

Odd Erik Johansen

Jyothis T. George

Maximilian von Eynatten

Julio Rosenstock

Vlado Perkovic

Christoph Wanner

Mark E. Cooper

John H. Alexander

Issei Komuro

Masaomi Nangaku

机构：

[1] Kyoto University,Department of Diabetes, Endocrinology and Nutrition, Graduate School of Medicine

[2] China-Japan Friendship Hospital,Department of Endocrinology

[3] Juntendo University Graduate School of Medicine,Department of Metabolism and Endocrinology

[4] Peking University People’s Hospital,Department of Endocrinology and Metabolism

[5] Boehringer Ingelheim Pharma GmbH & Co KG,Dallas Diabetes Research Center at Medical City

[6] Boehringer Ingelheim Pharma GmbH & Co KG,George Institute for Global Health, Faculty of Medicine

[7] Nippon Boehringer Ingelheim Co.,Division of Nephrology, Department of Medicine

[8] Ltd,Department of Diabetes, Central Clinical School

[9] Boehringer Ingelheim Norway KS,Department of Cardiovascular Medicine

[10] Boehringer Ingelheim International GmbH,Division of Nephrology and Endocrinology

[11] University of Texas Southwestern Medical Center,undefined

[12] University of New South Wales,undefined

[13] Würzburg University Clinic,undefined

[14] Monash University,undefined

[15] Duke Clinical Research Institute,undefined

[16] Duke Health,undefined

[17] University of Tokyo Hospital,undefined

[18] The University of Tokyo Graduate School of Medicine,undefined

来源：

Diabetology International | 2020年 / 11卷

关键词：

Diabetes mellitus, type 2; Cardiovascular diseases; Renal insufficiency, chronic; Prescription drugs;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：129 / 141

页数：12

共 50 条

[1] Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial
Inagaki, Nobuya
Yang, Wenying
Watada, Hirotaka
Ji, Linong
Schnaidt, Sven
Pfarr, Egon
Okamura, Tomoo
Johansen, Odd Erik
George, Jyothis T.
von Eynatten, Maximilian
Rosenstock, Julio
Perkovic, Vlado
Wanner, Christoph
Cooper, Mark E.
Alexander, John H.
Komuro, Issei
Nangaku, Masaomi
DIABETOLOGY INTERNATIONAL, 2020, 11 (02) : 129 - 141
[2] Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo-controlled CARMELINA® trial
Cooper, Mark E.
Rosenstock, Julio
Kadowaki, Takashi
Seino, Yutaka
Wanner, Christoph
Schnaidt, Sven
Clark, Douglas
Johansen, Odd Erik
DIABETES OBESITY & METABOLISM, 2020, 22 (07): : 1062 - 1073
[3] Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial
Biessels, Geert Jan
Verhagen, Chloe
Janssen, Jolien
van den Berg, Esther
Zinman, Bernard
Rosenstock, Julio
George, Jyothis T.
Passera, Anna
Schnaidt, Sven
Johansen, Odd Erik
DIABETES CARE, 2019, 42 (10) : 1930 - 1938
[4] Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial
Wanner, Christoph
Cooper, Mark E.
Johansen, Odd Erik
Toto, Robert
Rosenstock, Julio
McGuire, Darren K.
Kahn, Steven E.
Pfarr, Egon
Schnaidt, Sven
von Eynatten, Maximilian
George, Jyothis T.
Gollop, Nicholas D.
Marx, Nikolaus
Alexander, John H.
Zinman, Bernard
Perkovic, Vlado
CLINICAL KIDNEY JOURNAL, 2021, 14 (01) : 226 - 236
[5] Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial
Perkovic, Vlado
Toto, Robert
Cooper, Mark E.
Mann, Johannes F. E.
Rosenstock, Julio
McGuire, Darren K.
Kahn, Steven E.
Marx, Nikolaus
Alexander, John H.
Zinman, Bernard
Pfarr, Egon
Schnaidt, Sven
Meinicke, Thomas
von Eynatten, Maximillian
George, Jyothis T.
Johansen, Odd Erik
Wanner, Christoph
DIABETES CARE, 2020, 43 (08) : 1803 - 1812
[6] Effect of linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulfonylurea glimepiride on cardiovascular outcomes in Asians with type 2 diabetes: subgroup analysis of the randomized CAROLINA® trial
Kadowaki, Takashi
Wang, Guang
Rosenstock, Julio
Yabe, Daisuke
Peng, Yongde
Kanasaki, Keizo
Mu, Yiming
Mattheus, Michaela
Keller, Annett
Okamura, Tomoo
Johansen, Odd Erik
Marx, Nikolaus
DIABETOLOGY INTERNATIONAL, 2021, 12 (01) : 87 - 100
[7] Effect of linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulfonylurea glimepiride on cardiovascular outcomes in Asians with type 2 diabetes: subgroup analysis of the randomized CAROLINA® trial
Takashi Kadowaki
Guang Wang
Julio Rosenstock
Daisuke Yabe
Yongde Peng
Keizo Kanasaki
Yiming Mu
Michaela Mattheus
Annett Keller
Tomoo Okamura
Odd Erik Johansen
Nikolaus Marx
Diabetology International, 2021, 12 : 87 - 100
[8] Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA
McGuire, Darren K.
Alexander, John H.
Johansen, Odd Erik
Perkovic, Vlado
Rosenstock, Julio
Cooper, Mark E.
Wanner, Christoph
Kahn, Steven E.
Toto, Robert D.
Zinman, Bernard
Baanstra, David
Pfarr, Egon
Schnaidt, Sven
Meinicke, Thomas
George, Jyothis T.
von Eynatten, Maximilian
Marx, Nikolaus
Aizenberg, D.
Fiorella, A.
Edgardo, N.
Belen, C. Ianina
Alonso, P.
Walter, M.
Maia, K.
Guillermo, S.
Leandro, B.
Constanza, R. M.
Alejandra, N. M.
Melina, C.
Ariel, I. L.
Martin, S.
Rodrigo, C.
Alvarez, C.
Jorge, M. Z.
Gabriel, C.
German, S.
Bartolacci, I.
Bolobanich, G. A.
Tale, T.
Meritano, M.
Echeverria, M. G.
Gerrini, S. P.
Alvarez, M. R. y
Torrijos, N.
Berli, M.
Coggiola, J.
Castaneda, G.
Rode, R.
Milessi, R.
Roude, A.
CIRCULATION, 2019, 139 (03) : 351 - 361
[9] Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
Wanner, Christoph
Lachin, John M.
Inzucchi, Silvio E.
Fitchett, David
Mattheus, Michaela
George, Jyothis
Woerle, Hans J.
Broedl, Uli C.
von Eynatten, Maximilian
Zinman, Bernard
Aizenberg, D.
Ulla, M.
Waitman, J.
De Loredo, L.
Farias, J.
Fideleff, H.
Lagrutta, M.
Maldonado, N.
Colombo, H.
Ferre Pacora, F.
Wasserman, A.
Maffei, L.
Lehman, R.
Selvanayagam, J.
d'Emden, M.
Fasching, P.
Paulweber, B.
Toplak, H.
Luger, A.
Drexel, H.
Prager, R.
Schnack, C.
Schernthaner, G.
Fliesser-Goerzer, E.
Kaser, S.
Scheen, A.
Van Gaal, L.
Hollanders, G.
Kockaerts, Y.
Capiau, L.
Chachati, A.
Persu, A.
Hermans, M.
Vantroyen, D.
Vercammen, C.
Van de Borne, P.
Mathieu, C.
Benhalima, K.
Lienart, F.
Mortelmans, J.
CIRCULATION, 2018, 137 (02) : 119 - 129
[10] Analyses of First plus Recurrent Cardiovascular and Hospitalization Events in the Cardiovascular and Renal Microvascular Outcome Study with Linagliptin (CARMELINA) in Patients with Type 2 Diabetes and Cardiorenal Disease
Marx, Nikolaus
Mcguire, Darren K.
Johansen, Odd Erik
Rosenstock, Julio
Kahn, Steven E.
Cooper, Mark E.
Toto, Robert D.
Wanner, Christoph
Pfarr, Egon
Schnaidt, Sven
George, Jyothis
Von Eynatten, Maximilian
Perkovic, Vlado
Zinman, Bernard
Alexander, John H.
DIABETES, 2019, 68

← 1 2 3 4 5 →